3.18
+0.04(+1.27%)
Currency In USD
Address
2 Corporate Drive
South San Francisco, CA 94080
United States of America
Phone
(650) 382-3281
Website
Sector
Healthcare
Industry
Biotechnology
Employees
34
First IPO Date
May 26, 2021
| Name | Title | Pay | Year Born |
| Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder, Chief Executive Officer & Director | 630,788 | 1981 |
| Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director | 43,875 | 1966 |
| Dr. Kanya Rajangam M.D., Ph.D. | President, Head of Research & Development and Chief Medical Officer | 794,047 | 1974 |
| Mr. Faraz Siddiqui | Senior Vice President of Technical Operations | 0 | N/A |
| Mr. Thomas P. Chung | Vice President of Strategic Finance & Corporate Development | 0 | N/A |
| Mr. Jay Cross | Chief Financial Officer | 0 | 1971 |
| Dr. Wilson Wong Ph.D. | Scientific Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Mr. Robert H. Cutler J.D. | Senior Vice President & Head of Legal Affairs | 0 | 1968 |
| Ms. Dee Olomajeye Dragon | Vice President of People & Culture Strategy & Head of Administrative Operations | 0 | N/A |
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
